Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)
India · Delayed Price · Currency is INR 1,120.00
+41.75 (3.87%)
Last updated: Sep 7, 2026, 10:55 AM IST
Symbiotec Pharmalab Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 8,691 | 7,516 | 7,162 | 5,665 | 6,818 |
Other Revenue | - | - | - | - | 0.01 |
| 8,691 | 7,516 | 7,162 | 5,665 | 6,818 | |
Revenue Growth | 15.65% | 4.93% | 26.43% | -16.91% | - |
Cost of Revenue | 3,443 | 3,191 | 3,403 | 3,077 | 3,522 |
Gross Profit | 5,248 | 4,324 | 3,759 | 2,588 | 3,296 |
Selling, General & Admin | 1,567 | 1,245 | 1,050 | 947.4 | 836.35 |
Other Operating Expenses | 1,278 | 1,037 | 981.82 | 913.41 | 1,130 |
Operating Expenses | 3,377 | 2,713 | 2,420 | 2,146 | 2,225 |
Operating Income | 1,871 | 1,611 | 1,339 | 441.96 | 1,072 |
Interest Expense | -240.33 | -141.13 | -57.45 | -53.83 | -6.04 |
Interest & Investment Income | 3.39 | 7.48 | 3.27 | 13.35 | 11.22 |
Earnings From Equity Investments | - | -1.55 | -13.66 | -10.75 | 2.4 |
Currency Exchange Gain (Loss) | -22.35 | -3.34 | 43.25 | -25.08 | -16.97 |
Other Non Operating Income (Expenses) | -8.2 | -5.66 | -4.61 | 8.87 | -5.51 |
EBT Excluding Unusual Items | 1,604 | 1,467 | 1,310 | 374.52 | 1,057 |
Gain (Loss) on Sale of Investments | - | - | - | 0.03 | 0.06 |
Gain (Loss) on Sale of Assets | 19.62 | -2.73 | 0.07 | 0.25 | -0.61 |
Other Unusual Items | -89.93 | - | - | - | - |
Pretax Income | 1,534 | 1,470 | 1,310 | 382.68 | 1,057 |
Income Tax Expense | 434.6 | 501.9 | 309.28 | 147.82 | 281.79 |
Earnings From Continuing Operations | 1,099 | 967.85 | 1,001 | 234.86 | 775.27 |
Minority Interest in Earnings | -0.21 | -0.01 | 1.2 | - | - |
Net Income | 1,099 | 967.84 | 1,002 | 234.86 | 775.27 |
Net Income to Common | 1,099 | 967.84 | 1,002 | 234.86 | 775.27 |
Net Income Growth | 13.53% | -3.38% | 326.53% | -69.71% | - |
Shares Outstanding (Basic) | 58 | 56 | 56 | 55 | 55 |
Shares Outstanding (Diluted) | 58 | 56 | 56 | 55 | 55 |
Shares Change | 3.71% | 0.17% | 1.80% | - | - |
EPS (Basic) | 19.10 | 17.39 | 18.00 | 4.30 | 14.18 |
EPS (Diluted) | 19.00 | 17.36 | 18.00 | 4.30 | 14.18 |
EPS Growth | 9.45% | -3.54% | 319.01% | -69.71% | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -511.26 | -2,609 | -222.69 | -1,552 | -546.39 |
Free Cash Flow Per Share | -8.84 | -46.78 | -4.00 | -28.37 | -9.99 |
Gross Margin | 60.39% | 57.54% | 52.49% | 45.68% | 48.34% |
Operating Margin | 21.53% | 21.43% | 18.69% | 7.80% | 15.72% |
Profit Margin | 12.64% | 12.88% | 13.99% | 4.15% | 11.37% |
Free Cash Flow Margin | -5.88% | -34.71% | -3.11% | -27.39% | -8.01% |
EBITDA | 2,391 | 2,031 | 1,720 | 727.18 | 1,330 |
EBITDA Margin | 27.51% | 27.02% | 24.01% | 12.84% | 19.50% |
D&A For EBITDA | 519.13 | 420.14 | 380.61 | 285.22 | 258.28 |
EBIT | 1,871 | 1,611 | 1,339 | 441.96 | 1,072 |
EBIT Margin | 21.53% | 21.43% | 18.69% | 7.80% | 15.72% |
Effective Tax Rate | 28.34% | 34.15% | 23.61% | 38.63% | 26.66% |
Revenue as Reported | 8,723 | 7,560 | 7,233 | 5,730 | 6,848 |
Advertising Expenses | 23.2 | 22.48 | 9.57 | 6.65 | 5 |